Mid-sized drug maker, Venus Remedies has received approval for market authorization from MHRA (UK) via DCP route ( which covers Ireland, Poland, Slovenia, Netherlands, Finland, Austria, Slovakia, Denmark, Germany, Sweden, France and Italy also) for its generic board spectrum injectable antibiotic carbapenem. The company is all set to launch this drug soon within this fiscal year. Besides, this Venus has also got market authorization for the same product from New Zealand’s Ministry of Health.
Market authorization grants from both territories have opened doors for Venus to enter into the highly lucrative penems market of $250 million in Europe and $20 million in New Zealand. Meropenem market authorization grants once again proved company’s R&D capabilities and its expertise in developing world class products with regulatory might.
Meropenem is a broad spectrum anti-bacterial agent of carbapenem family indicated as empirical therapy prior to the identification of causative organism, or for disease caused by single or multiple susceptible bacteria in both adults and children with a broad range of serious infections. At present, Meropenem sales accounts for $906 million across the globe, which is estimated to grow to $1,006 million by 2012.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1518.85 |
Dr. Reddys Lab | 5761.00 |
Cipla | 1408.10 |
Zydus Lifesciences | 1007.20 |
Lupin | 1654.70 |
View more.. |